Trial
NCT05513391
Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi Pasteur, a Sanofi Company
Collaborators
—
Condition
Influenza Immunization
Intervention
Recombinant influenza vaccine (RIV4)
Why stopped
Sponsor decision to prematurely stop the study. This decision was made without any safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-09